News stories about Accelerate Diagnostics (NASDAQ:AXDX) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Accelerate Diagnostics earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 46.4905841303801 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- Pacific Biosciences of California (PACB) vs. Accelerate Diagnostics (AXDX) Head-To-Head Survey (americanbankingnews.com)
- Noteworthy Tuesday Option Activity: CAR, SAIC, AXDX (nasdaq.com)
- $2.17 Million in Sales Expected for Accelerate Diagnostics Inc (AXDX) This Quarter (americanbankingnews.com)
- Brokerages Expect Accelerate Diagnostics Inc (AXDX) Will Announce Earnings of -$0.37 Per Share (americanbankingnews.com)
A number of equities research analysts recently issued reports on the company. ValuEngine upgraded Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Monday. Craig Hallum began coverage on Accelerate Diagnostics in a research note on Thursday, May 24th. They issued a “hold” rating and a $25.00 target price on the stock. BidaskClub raised Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research note on Friday, May 18th. Zacks Investment Research cut Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, May 14th. Finally, BTIG Research reissued a “hold” rating on shares of Accelerate Diagnostics in a research note on Sunday, February 18th. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. Accelerate Diagnostics presently has a consensus rating of “Hold” and a consensus target price of $29.50.
Accelerate Diagnostics (NASDAQ:AXDX) last released its earnings results on Wednesday, May 9th. The medical research company reported ($0.27) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.05. The business had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $2.64 million. Accelerate Diagnostics had a negative return on equity of 51.23% and a negative net margin of 1,568.29%. sell-side analysts anticipate that Accelerate Diagnostics will post -1.38 earnings per share for the current fiscal year.
In other news, Director Jack W. Schuler bought 100,000 shares of Accelerate Diagnostics stock in a transaction that occurred on Friday, May 11th. The shares were acquired at an average price of $19.33 per share, with a total value of $1,933,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jack W. Schuler bought 65,000 shares of Accelerate Diagnostics stock in a transaction that occurred on Monday, May 14th. The stock was purchased at an average cost of $19.97 per share, for a total transaction of $1,298,050.00. The disclosure for this purchase can be found here. 49.30% of the stock is owned by corporate insiders.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.